Biocon Ltd is seeking regulatory approval for its generic version of Ozempic (semaglutide) to get into Canada's high growth obesity drug market, aiming for a submission date of September 2025. This would allow for a...
In a strategic shift to develop its position in India’s growing self-care and over-the-counter (OTC) market, Lupin Limited has formally separated its consumer healthcare division and formed a wholly owned subsidiary called LupinLife Consumer...
With nearly $2 billion in yearly revenues, which is already a record for India's fragmented drug-retailing industry, Apollo Hospitals Enterprises (AHEL), the largest listed healthcare chain in the nation, and its subsidiary Apollo HealthCo
Torrent Pharmaceuticals has become the fifth largest pharmaceuticals company in India by domestic market share when it purchased a controlling stake in JB Chemicals & Pharmaceuticals. This deal is one of the largest mergers in India's...
Biocon Biologics reported that Biocon Sdn. Bhd., its Malaysian subsidiary, has exceeded the milestone of providing the Malaysian Ministry of Health (MoH) with 100 million recombinant human insulin (rh-insulin) cartridges.
Alembic Pharmaceuticals Limited has received final approval of the U.S. Food and Drug Administration (USFDA) on its generic Doxorubicin Hydrochloride Liposome Injection (10 mg/5 mL, 20 mg/10 mL and 50 mg/25 mL) in single dose ampoule...
Eli Lilly has announced that its diabetes and obesity medicine, Mounjaro, will be available in a prefilled pen format in India, which can increase competition in the fast-growing chronic care space. The company received approval from the Central...
.jpeg)
The 5th South Asia Regional Chapter Meeting during the USP Convention 2025 featured industry professionals and stakeholders gathering around key issues of improving the quality of Active Pharmaceutical Ingredient (API) production.
In order to buy its 47.84 percent share in J B Chemicals and Pharmaceuticals (JB Pharma), Gujarat-based Torrent Pharmaceuticals Limited has reopened negotiations with private equity (PE) company KKR
Biocon, an Indian biotech giant, has opted to withdraw plans to launch weight-loss drugs in China, reversing course as global growth for semaglutide-based weight-loss drugs builds. This decision comes as Novo Nordisk is also doubling down on its...
.jpg)
, CDSCO.jpg)